Updates

NeuroIntact is proud to announce that our INTACT Trial has begun enrolling patients, led by Principal Investigator Neeraj Badjatia, MD.

As a Maryland-based company, it is especially meaningful to be working with the University of Maryland Department of Neurosurgery and Neurocritical Care Program at the R Adams Cowley Shock Trauma Center.

Our VCool™ System is being evaluated for its safety and performance in febrile ICU patients, with the goal of helping clinicians maintain targeted temperature control. A major milestone for NeuroIntact and VCool™.

NeuroIntact was invited to attend Emergency Neurological Life Support (ENLS) from the Neurocritical Care Society at Temple Health – Temple University Health System.

The course provided a compelling look at how temperature plays a critical role in patient care. We are grateful to Lauren Koffman DO, MS, FCCM for the invitation and for her valuable feedback on the NeuroIntact product portfolio.

Lars Hungerford hosted "Managing the Golden Hour & Beyond: Innovative TBI Care in Contested Combat Environments" with J.B. Phillips, Ph.D., MBA, PMP. It was meaningful to see DC's MedStar Health Neurosurgeon Rocco Anthony Armonda in Ukraine supporting the mission.

NeuroIntact took the time to listen to the military need for new non-invasive diagnostics for TBI patients. Working alongside MTEC (Medical Technology Enterprise Consortium) and the Uniformed Services University, we will continue to partner with the Military.

NeuroIntact, founded in 2023 by Bryan Nicholson, offers an advance in precision temperature modulation for hospitalized patients. Its flagship system, VCool, was developed with direct feedback from world-renowned physicians in the United States and internationally.

The company recently published its first-in-human study in the peer-reviewed journal, Therapeutic Hypothermia and Temperature Management. The study demonstrated measurable core temperature reduction with strong tolerability — participants remained awake and required no adjunctive pharmaceuticals during therapy.

"Temperature is protective," said Nicholson. "It should be delivered with precision, portability and patient-centered design."

TEDCO seed funds invested $250,000 in NeuroIntact's seed round of $5.5 million in the fall of 2025. As it moves into 2026, NeuroIntact is focused on regulatory advancement, expanded clinical validation, and continued execution of its military and commercial strategies.

NeuroIntact published its first peer-reviewed study: "Intranasal Temperature Modulation Device in Awake Healthy Volunteers: A First In-Human Safety and Tolerability Study."

Thank you to Alan N. and Neeraj Badjatia for your support with this study and future research. Cooling awake volunteers to the 35°C range with no adjunct medications is a significant and promising result.

This milestone advances NeuroIntact's mission to deliver safe, drug-free temperature modulation for stroke and traumatic brain injury patients.

NeuroIntact is excited to announce Dr. Charles Edwards II to the Board of Directors. As a physician, Dr. Edwards brings a critical clinical perspective to the board as NeuroIntact commercializes its VCool™ technology.

"The more I learn about VCool, the more intuitive it is. Our bodies have been designed with our sinuses — a large surface area for humidifying and warming the air we breathe — but that can also be used to cool our body in reverse. It's almost as if God had designed a process for body cooling using the sinuses. And that's what VCool does," said Dr. Edwards.

NeuroIntact is also announcing the close of its Seed Round at $5.5M. Thanks to all investors for their support: Neuvation Ventures, Riptide Ventures, TEDCO, Central Texas Angel Network, Chris Kager MD MBA, Marcio Souza, Livingston Capital Ventures LP, Jared Slosberg, Mahesh Narayanan, Teddy Gresser, Bill Niland, Phillip Attia, and Leo Pruissen.

NeuroIntact attended MEDICA, the world's leading international trade fair for the medical industry, thanks to a grant from the Maryland Department of Commerce for selecting NeuroIntact to attend.

A special thank you to Brian Castleberry and Paul Matino for their tremendous support. Marc McKenna had the opportunity to meet excellent international distributors for VCool™ — a major step forward in our global commercialization strategy.

Our NeuroIntact team presented our VCool™ technology at the SBIR Expo at Marine Corps Base Quantico, introducing our technology to several military forces.

The mission behind this work is deeply personal. Bryan Nicholson's father, Bill Nicholson, is a Marine who was shot in the head on 9/11 and blown up on 11/8 in the Vietnam War, sustaining traumatic brain injuries. He has always said, "Stay Close to the Marines." It's an amazing feeling to invent a device to preserve the brain.

"I'm proud to be the son of a Marine and continue this journey." — Bryan Nicholson, Founder & President

NeuroIntact was accepted at the Neurocritical Care Society (NCS) to present our first study with VCool™. Cooling awake patients is a paradigm shift from the current available temperature management devices, which require adjunct pharmaceuticals for sedation and paralytics.

We appreciate the support of our scientific advisors, including Neeraj Badjatia and Alan N., whose guidance was instrumental in getting our first article published and advancing further research.

NeuroIntact has appointed Robert Kline to its Board of Directors. Kline's 25 years of success growing innovative companies in the temperature management space will advance the company's pathway toward commercialization of its intranasal delivery method for targeted temperature management (TTM).

Kline is considered one of the pioneers of TTM as the founder of Medivance, acquired by C. R. Bard for approximately $250 million in 2011. He also co-founded ViroCyt (acquired by Sartorius AG in 2016) and served as CEO of Bolder Surgical (acquired by Hologic for $160 million in 2021).

"NeuroIntact's non-invasive intranasal delivery technology to cool the brain represents a sea change in TTM, and I am extremely enthusiastic about its potential," said Kline. "NeuroIntact's cooling approach can be administered without the use of sedation drugs, and with the benefit of nonexistent patient shivering."

NeuroIntact has received a U.S. patent for its VCool system and method for cooling the brain of a human subject — a significant milestone validating the company's innovative approach to non-invasive intranasal temperature modulation.

Compared with similar products on the market, VCool has fewer side effects. It is intranasal and non-invasive, engineered to provide controlled core body temperature modulation in a portable, practical platform suited for hospital environments and critical-care settings.